Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia

被引:37
作者
Hessling, J [1 ]
Kröger, N [1 ]
Werner, M [1 ]
Zabelina, T [1 ]
Hansen, A [1 ]
Kordes, U [1 ]
Ayuk, FA [1 ]
Renges, H [1 ]
Panse, J [1 ]
Erttmann, R [1 ]
Zander, AR [1 ]
机构
[1] Univ Hosp Hamburg Eppendorf, D-20246 Hamburg, Germany
关键词
allogeneic stem cell transplantation; dose-reduced conditioning; non-myeloablative transplantation; graft-versus-host disease; myelofibrosis with myeloid metaplasia;
D O I
10.1046/j.1365-2141.2002.03884.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three patients with myelofibrosis received allogeneic stem cell transplantation after a dose- reduced conditioning regimen of busulphan ( 8 mg/ kg), fludarabine (180 mg/m(2)) and antithymocyte globulin (4 x 10 mg/ kg). The median age at transplantation was 51 years ( range 44 - 58). All patients engrafted with a leucocyte count > 1.0 x 10(9)/I after a median of 18 d ( range 16 - 20). Grade II acute skin graft- versus- host disease ( GvHD) occurred in one patient. One limited and one extensive chronic GvHD was observed. All patients achieved complete haematological remission. In one patient the fibrosis resolved completely 180 d post transplant. All patients are alive 126, 466 and 764 d after transplantation.
引用
收藏
页码:769 / 772
页数:4
相关论文
共 12 条
[1]   Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines [J].
Barosi, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2954-2970
[2]  
Byrne JL, 2000, BRIT J HAEMATOL, V108, P430
[3]   Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect [J].
Cervantes, F ;
Rovira, M ;
Urbano-Ispizua, A ;
Rozman, M ;
Carreras, E ;
Montserrat, E .
BONE MARROW TRANSPLANTATION, 2000, 26 (06) :697-699
[4]   Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups [J].
Cervantes, F ;
Barosi, G ;
Demory, JL ;
Reilly, J ;
Guarnone, R ;
Dupriez, B ;
Pereira, A ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) :684-690
[5]   Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia [J].
Devine, SM ;
Hoffman, R ;
Verma, A ;
Shah, R ;
Bradlow, BA ;
Stock, W ;
Maynard, V ;
Jessop, E ;
Peace, D ;
Huml, M ;
Thomason, D ;
Chen, YH ;
van Besien, K .
BLOOD, 2002, 99 (06) :2255-2258
[6]  
Dupriez B, 1996, BLOOD, V88, P1013
[7]  
Guardiola P, 1999, BLOOD, V93, P2831
[8]   Anti-Thymocyte-Globulin as part of the preparative regimen prevents graft failure and severe Graft versus Host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors [J].
Kröger, N ;
Zabelina, T ;
Krüger, W ;
Renges, H ;
Stute, N ;
Dürken, M ;
von Finkenstein, FG ;
Erttmann, R ;
Kabisch, H ;
Schafhausen, P ;
Jaburg, N ;
Löliger, C ;
Zander, AR .
ANNALS OF HEMATOLOGY, 2001, 80 (04) :209-215
[9]   Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects [J].
McSweeney, PA ;
Niederwieser, D ;
Shizuru, JA ;
Sandmaier, BM ;
Molina, AJ ;
Maloney, DG ;
Chauncey, TR ;
Gooley, TA ;
Hegenbart, U ;
Nash, RA ;
Radich, J ;
Wagner, JL ;
Minor, S ;
Appelbaum, FR ;
Bensinger, WI ;
Bryant, E ;
Flowers, MED ;
Georges, GE ;
Grumet, FC ;
Kiem, HP ;
Torok-Storb, B ;
Yu, G ;
Blume, KG ;
Storb, RF .
BLOOD, 2001, 97 (11) :3390-3400
[10]   Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases [J].
Slavin, S ;
Nagler, A ;
Naparstek, E ;
Kapelushnik, Y ;
Aker, M ;
Cividalli, G ;
Varadi, G ;
Kirschbaum, M ;
Ackerstein, A ;
Samuel, S ;
Amar, A ;
Brautbar, C ;
Ben-Tal, O ;
Eldor, A ;
Or, R .
BLOOD, 1998, 91 (03) :756-763